how to play jili games

Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif. , Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations. "I'm pleased to welcome three industry leaders to our Kyverna team," said Warner Biddle , Chief Executive Officer of Kyverna. "Dan, Cara and Tracy bring important new skills and capabilities to Kyverna as we continue to support the company's next phase of growth and work to bring a transformative change to patients living with severe autoimmune diseases." Mr. Maziasz brings over 25 years of leadership and business experience across several leading biotechnology and large pharmaceutical companies. Mr. Maziasz most recently served as Chief Business Officer at Atara Biotherapeutics, the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. At Atara, Mr. Maziasz led various corporate initiatives including strategic planning, licensing transactions with industry partners, and research collaborations with academic groups. Before his time at Atara, Mr. Maziasz was Vice President, Corporate Strategy and Business Development at Kite Pharma, a global cell therapy leader, prior to its acquisition by Gilead Sciences. Mr. Maziasz also spent more than a decade at Amgen, where he held roles of increasing responsibility in the US, Europe , and Asia across business development, corporate strategy, finance, and commercial functions. Ms. Bauer brings more than 25 years of experience in global human resources leadership to Kyverna, having served most recently as Global Head of Human Resources at Kite, a Gilead Company, where she oversaw all HR strategy and operations during a period of hypergrowth and global expansion which strengthened the company's leadership position in cell therapy. Prior to this role, she served as the Global Head of HR for the Entertainment Division at Riot Games where she worked directly with the founders to build an Entertainment Studio separate from the core gaming business. Ms. Bauer has also held various HR leadership roles at companies such as Netflix, Amgen, Gartner and Novo Nordisk. Ms. Rossin brings more than 20 years of strategic communications experience to Kyverna, having most recently served as the Head of Public Affairs at Kite, where she was responsible for leading corporate, product and employee communications in addition to patient advocacy. Prior to this role, she served as Vice President, Global Head of Communications at Innate Pharma, an oncology-focused biotech company, where she led both corporate and financial communications. Ms. Rossin also spent more than 12 years at AstraZeneca/MedImmune, where she held multiple U.S. and global communications roles for key therapeutic areas across AstraZeneca's portfolio before serving as the Head of Corporate Affairs at MedImmune, the global biologics research and development arm of AstraZeneca. Before joining AstraZeneca, she held various positions at global public relations agencies working with corporate and healthcare related clients. Inducement Grant In connection with the appointment of Mr. Maziasz as Kyverna's Chief Business Officer, on December 9, 2024 , Kyverna granted Mr. Maziasz an option to purchase 350,000 shares of its common stock (Option). The Option was granted pursuant to the Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan, as approved by the Compensation Committee of Kyverna's Board of Directors on September 14, 2024 , and was granted as an inducement material to Mr. Maziasz's employment with Kyverna in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option was $4.86 , the closing price of Kyverna's common stock on December 9, 2024 , the date of grant. The Option will vest over four years, with 25% of the total number of shares subject to the Option vesting on the one-year anniversary of Mr. Maziasz's appointment and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Maziasz's continued service to Kyverna on each vesting date. Kyverna is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit https://kyvernatx.com . Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential impact of the clinical outcomes from the ongoing clinical programs; the potential impact of the new data on the treatment efficacy and safety profile of KYV-101; the potential that the results of the ongoing trials could drastically change the treatment landscape for the targeted autoimmune diseases; Kyverna's goals to develop certain paradigm-shifting treatment options; the potential for KYV-101 to provide durable, immunosuppressant-free remission for autoimmune disease patients; Kyverna's beliefs about the differentiated properties of KYV-101; and Kyverna's clinical trials, investigator-initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contact: Investors: InvestorRelations@kyvernatx.com Media: media@kyvernatx.com View original content to download multimedia: https://www.prnewswire.com/news-releases/kyverna-therapeutics-strengthens-leadership-team-to-accelerate-next-phase-of-growth-302331659.html SOURCE Kyverna Therapeutics

Marvell Technology, Inc. Declares Quarterly Dividend PaymentAssad’s secret police arrested and tortured me four times. My crime? I had same name as a wanted manOne Bio Secures $27 Million in Series A Funding to Revolutionize Nutrition with Launch of Breakthrough Technology Making High-Dose, Anti-Inflammatory Plant Fiber Imperceptible in Food and Beverage for the First Time

Breyten Breytenbach, who died Sunday, was one of South Africa's most honoured writers, who found beauty in his Afrikaans language but was horrified at the white supremacy imposed by his government. The poet, author and painter had not lived in South Africa for decades, leaving in the early 1960s to settle in Paris, where he became a global voice against apartheid. What was intended to be a short and secret trip back in 1975 led to him spending seven years in jail, two in solitary confinement, after he was betrayed and arrested. French president Francois Mitterrand helped secure his release in 1982 and he returned to France to become a citizen. He travelled back to South Africa regularly, according to his daughter Daphnee Breytenbach, who confirmed his death to AFP. "My father, the South African painter and poet Breyten Breytenbach, died peacefully on Sunday, November 24, in Paris, at the age of 85," she said. "Immense artist, militant against apartheid, he fought for a better world until the end." Breytenbach was born in the small Western Cape town of Bonnievale in 1939 at a time when Afrikaans was emerging with a distinct identity as a language, having been derided as "kitchen Dutch". When in 1964 Breytenbach published his first volume of poetry -- "Die ysterkoei moet sweet", or The Iron Cow Must Sweat -- Afrikaans was not just ascendent but had given the name "apartheid" to South Africa's brutal system of racial segregation. With Afrikaners in power, their language became ever more associated with the regime. "I'd never reject Afrikaans as a language, but I reject it as part of the Afrikaner political identity. I no longer consider myself an Afrikaner," he said in an interview with The New York Times the following year. In his language and politics, Breytenbach pushed back against the strictures of the country in which he was born. He travelled around Europe in his early 20s, eventually settling in 1962 in Paris, where he met his wife, Yolande Ngo Thi Hoang Lien, who was born in Vietnam and raised in France. She was refused a visa to visit South Africa in the late 1960s as she was considered "non-white" by the apartheid system. Breytenbach returned to the country in the early 1970s on a false passport to deliver money to the anti-apartheid struggle and meet white activists. But he was discovered and sentenced to nine years in prison, serving seven. Of his more than 50 books, most are in Afrikaans. His acclaimed 1984 prison memoir, "The True Confession of an Albino Terrorist", is in English. In the book, he recalls the horrors of hearing fellow inmates being hanged, often for political crimes. "Very often –- no, all the time really –- I relive those years of horror and corruption, and I try to imagine, as I did then with the heart an impediment to breathing, what it must be like to be executed. What it must be like to be. Executed," he wrote. His path crossed once, briefly, with another famous inmate. Nelson Mandela was for a time transferred from Robben Island to Pollsmoor prison in Cape Town, where Breytenbach was serving his time. The writer was tasked with preparing new prison clothes for the future president. Breytenbach eventually turned to painting to portray surreal human and animal figures, often in captivity, with his art displayed in Johannesburg, Brussels, Amsterdam, Hong Kong and Paris. His literature gathered several prizes, including the international Zbigniew Herbert International Literary Award (2017), the Mahmoud Darwish Literature Prize (2010) and the Van der Hoogt prize for Dutch literature (1972). "His poems are rich in metaphors and are a complex mixture of references to Buddhism, Afrikaans idiomatic speech, and memories of the South African landscape," according to the Hague-based Writers Unlimited foundation. For all his activism, when democracy arrived in 1994, the older and gray-bearded Breytenbach did not return to embrace the new South Africa. He wrestled with the failings of the democratic government, even with Mandela, despairing at what he called in Harpers magazine in 2008 the "seemingly never-ending parade of corrupt clowns in power at all levels". Breytenbach also taught at the University of Cape Town, the Goree Institute in Dakar and New York University. zm-gs-br/lhd/js

Everything You Need to Know About Shingles & the Shingles VaccineHunter, Jeanty give Heisman ceremony a different vibeWhat 2024 meant for India’s higher education system

Martinez had gone eight matches since last finding the back of the net against Venezia on November 3 but after Alessandro Bastoni opened the scoring in the 54th minute, the Argentina international struck in Sardinia. The Inter captain took his tally against Cagliari to 10 goals in as many games after 71 minutes before Hakan Calhanoglu capped an excellent night for the visitors from the penalty spot a few moments later. This moment >>> #ForzaInter #CagliariInter pic.twitter.com/aZwbAZvRVI — Inter ⭐⭐ (@Inter_en) December 28, 2024 Inter’s fifth-successive league victory led to them temporarily leapfrogging Atalanta, who reclaimed top spot but saw their lead cut to a single point following a 1-1 draw at Lazio. Gian Piero Gasperini’s side were grateful for a point in the end after falling behind to Fisayo Dele-Bashiru’s first-half strike, only drawing level with two minutes remaining thanks to Marco Brescianini. Lautaro Valenti’s last-gasp strike condemned rock-bottom Monza to a 10th defeat in 18 matches as Parma edged a 2-1 victory, while Genoa defeated Empoli by the same scoreline.Will New Year's Eve be loud or quiet? What are the top 2025 resolutions? AP-NORC poll has answersHow to use KVM on your monitor

Share to Facebook Share to Twitter Share to Linkedin An aerial view of the Praia lighthouse in Cape Verde, one of the safest places to travel in 2025. What are the safest places to travel in 2025? A new report from International SOS—a leading security and health risk services company—offers key insights and practical guidance for travelers navigating an increasingly unpredictable world. International SOS recently released its annual Risk Map 2025 , which predicts what the coming year will hold—from the safest countries in the world to the riskiest ones, plus the biggest issues shaping the travel landscape. International SOS’s Risk Map assesses risks in four key areas: security, medical, climate and mental health risks. Countries are broken down into five levels of risk, ranging from insignificant to extreme, depending on the category. This year’s map also incorporates a more granular analysis, offering insights into more than 1,000 cities worldwide and the key factors driving risks, including conflict, crime, infrastructure and access to healthcare. Compare these results to last year’s report from International SOS, and you’ll notice a world grappling with many issues. According to International SOS, 65% of senior risk professionals believe risks have increased over the past year, with 69% predicting significant impacts from geopolitical challenges in 2025. Safest Places To Travel: Safest Countries So where should you travel in 2025 for peace of mind? As in previous years , Scandinavian countries top International SOS’s list of safest destinations, including Iceland, Norway, Denmark and Finland. These countries consistently rank high due to a combination of low crime rates, effective government policies and excellent emergency services. Iceland has also been named the safest country in the world in other reports. Iceland is one of the safest places for 2025. Pictured here: sunrise over Kirkjufell mountain with the Kirkjufellsfoss waterfall. Switzerland also makes International SOS’s list of safest countries, thanks to its political stability and low levels of crime. Smaller countries like Slovenia, Luxembourg and Greenland round out the group of places with “insignificant” security risks—more proof that stable governance and strong infrastructure are key to creating safe travel environments. Island nations such as Cape Verde, the Seychelles and the Marshall Islands are also standout destinations for safety on International SOS’s Risk Map. Cape Verde—off the west coast of Africa—is celebrated for its political stability and low crime rates. The Seychelles combines a welcoming culture with a tranquil environment east of Africa in the Indian Ocean. The Marshall Islands offers a peaceful escape in a remote location in the central Pacific Ocean. Safest Places To Travel: Riskiest Countries At the other end of the spectrum are the countries where risk runs high. Countries like Libya and Afghanistan remain among the riskiest destinations due to ongoing conflict, weak governance and a lack of infrastructure to manage security threats. In sub-Saharan Africa, places like Somalia and the Central African Republic are characterized by instability, high crime rates and fragile governments. The port of Bossaso in Somalia, one of the riskiest places to travel in 2025. “Geopolitical tensions have been the most prominent trigger, with changes to risk ratings for locations such as Sudan and Lebanon, where the intensity and expansion of conflict now impact more population centers and have pushed the overall risk rating up,” Sally Llewellyn, global security director at International SOS, said in a statement. Some other risky places that International SOS has earmarked include Syria, Yemen and the Sahel, where instability is worsening and external actors are propping up struggling governments. In Venezuela, the authoritarian rule continues to drive emigration, while Bolivia faces growing instability due to its declining economy. And the Russia-Ukraine conflict remains a stalemate, with neither side gaining ground. Several other places had increases in security risk ratings due to crime trends and increased social unrest. This includes South Africa, where the risk went from medium to high for the city of Johannesburg and eThekwini (which includes the city of Durban). In Mexico, growing cartel activity raised concerns for certain regions. Escalating social tensions in Kenya similarly led to increased risks. New Caledonia went from low to medium, based on impacts like social unrest, economic decline and related crime. And the Philippines, Thailand and Laos also had changes in risk ratings, due to reductions in militancy. International SOS didn’t decrease security risk ratings for any country in 2025. Safest Places To Travel: Medical Risks Access to quality healthcare is another big consideration for travelers. For 2025, International SOS’s list of lowest medical risk destinations includes countries like the United States, Canada, Japan, Australia and much of Europe. These places benefit from healthcare infrastructure, access to essential medicines and reliable emergency services. Japan is one of the safest countries when it comes to medical risks. Pictured here: a Japanese hospital. On the other haan countries like Afghanistan, North Korea and Somalia are rated as having very high medical risks. The reason? Limited healthcare access, insufficient resources and the prevalence of infectious diseases create significant challenges in these regions, which travelers should be aware of before planning a visit. Two countries with notable changes in medical risk this year are Bolivia (which went from medium to high) and Libya (which went from extreme to high). “Changes to medical risks are based on factors including the standard and access to healthcare facilities, availability of medicines and the prevalence of infections and diseases,” Dr. Katherine O’Reilly, regional medical director at International SOS said in a statement. Safest Places To Travel: Climate Risks The 2025 Risk Map also highlights the growing impact of climate change in travel planning, looking at the countries best equipped to handle its impacts. Scandinavian countries once again lead the way in minimizing climate-related risks. The reason: proactive environmental policies and resilient infrastructure. New Zealand is a low climate risk destination for 2025. Pictured here: Mitre Peak rising from the Milford Sound fiord. Other low climate risk destinations include New Zealand and the UAE, both of which are investing heavily in sustainability and adaptation measures and leveraging new technologies such as “digital twins” to improve land and water management, making them leaders in sustainability and adaptation. The places with the worst climate impacts include several Africa countries (Mali, Chad, Ethiopia), plus vulnerable places like the Philippines and India. According to International SOS, these already fragile areas are impacted by resource scarcity and extreme weather events. The 2025 Risk Map also highlights how innovation is playing a role in minimizing climate-related risks. For instance, the U.N.’s “Early Warnings for All” initiative aims to protect global populations from hazardous weather events through timely forecasting. Safest Places To Travel: Mental Health Risks Mental health is another major concern for travelers. The 2025 Risk Map evaluates countries based on rates of mental health challenges like anxiety, depression and stress-related illnesses. It also highlights how global factors like disinformation, political stress and climate anxiety are amplifying mental health challenges. Vietnam is a low-risk destination for mental health. Pictured here: Ha Long Bay. In countries like Vietnam, cultural attitudes and supportive social structures contribute to relatively low mental health risks. Similarly, Scandinavian countries like Iceland and Norway score lower on mental health risks due to their strong healthcare systems, societal well-being and emphasis on work-life balance. Meanwhile, countries like the United States rank higher on the mental health risk scale, reflecting broader societal challenges, including stress, burnout and limited access to mental health support in certain regions. These challenges are particularly acute in urban areas where stress levels are highest. Read on for lists of some of the safest countries to travel (based on places with “insignificant” security risk) and the riskiest countries to travel (places with “extreme” security risk). Countries are listed alphabetically. For additional insights, you can check out International SOS’s full Risk Outlook 2025 report here . The Seychelles is one of the safest countries to travel in 2025. Pictured here: Anse Source D'Argent beach on La Digue Island. Safest Countries To Travel In 2025 Cape Verde Denmark Finland Greenland Iceland Marshall Islands Norway San Merino Seychelles Slovenia Switzerland A view of Kabul in Afghanistan, one of the riskiest countries to travel in 2025. Riskiest Countries To Travel In 2025 Afghanistan Central African Republic Iraq Libya Somalia South Sudan Sudan Syria Ukraine Yemen MORE FROM FORBES: Editorial Standards Forbes Accolades Join The Conversation One Community. Many Voices. Create a free account to share your thoughts. Forbes Community Guidelines Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space. In order to do so, please follow the posting rules in our site's Terms of Service. We've summarized some of those key rules below. Simply put, keep it civil. Your post will be rejected if we notice that it seems to contain: False or intentionally out-of-context or misleading information Spam Insults, profanity, incoherent, obscene or inflammatory language or threats of any kind Attacks on the identity of other commenters or the article's author Content that otherwise violates our site's terms. User accounts will be blocked if we notice or believe that users are engaged in: Continuous attempts to re-post comments that have been previously moderated/rejected Racist, sexist, homophobic or other discriminatory comments Attempts or tactics that put the site security at risk Actions that otherwise violate our site's terms. So, how can you be a power user? Stay on topic and share your insights Feel free to be clear and thoughtful to get your point across ‘Like’ or ‘Dislike’ to show your point of view. Protect your community. Use the report tool to alert us when someone breaks the rules. Thanks for reading our community guidelines. Please read the full list of posting rules found in our site's Terms of Service.

Is he a hero? A killer? Both? About the same time the #FreeLuigi memes featuring the mustachioed plumber from “Super Mario Brothers” mushroomed online, commenters shared memes showing Tony Soprano pronouncing Luigi Mangione , the man charged with murdering the UnitedHealthcare CEO in Manhattan , a hero. There were posts lionizing Mangione’s physique and appearance, the ones speculating about who could play him on “Saturday Night Live,” and the ones denouncing and even threatening people at a Pennsylvania McDonald’s for spotting him and calling police. It was all too much for Pennsylvania's governor, a rising Democrat who was nearly the vice presidential nominee this year. Josh Shapiro — dealing with a case somewhere else that happened to land in his lap — decried what he saw as growing support for “vigilante justice.” The curious case of Brian Thompson and Luigi Mangione captivated and polarized a media-saturated nation. It also offers a glimpse into how, in a connected world, so many different aspects of modern American life can be surreally linked — from public violence to politics, from health care to humor (or attempts at it) . It summons a question, too: How can so many people consider someone a hero when the rules that govern American society — the laws — are treating him as the complete opposite? Luigi Mangione, a suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson, on Monday at the police station in Altoona, Pa. Writings found in Mangione's possession hinted at a vague hatred of corporate greed and an expression of anger toward “parasitic” health insurance companies. Bullets recovered from the crime scene had the words “deny,” “defend” and “depose,” reflecting words used by insurance industry critics, written on them. A number of online posts combine an apparent disdain for health insurers — with no mention of the loss of life. “He took action against private health insurance corporations is what he did. he was a brave italian martyr. in this house, luigi mangione is a hero, end of story!” one anonymous person said in a post on X that has nearly 2 million views. On Monday, Shapiro took issue with comments like those. It was an extraordinary moment that he tumbled into simply because Mangione was apprehended in Pennsylvania. Shapiro's comments — pointed, impassioned and, inevitably, political — yanked the conversation unfolding on so many people's phone screens into real life. “We do not kill people in cold blood to resolve policy differences or express a viewpoint,” the governor said. “In a civil society, we are all less safe when ideologues engage in vigilante justice.” But to hear some of his fellow citizens tell it, that's not the case at all. Like Bonnie and Clyde, John Dillinger, D.B. Cooper and other notorious names from the American past, Mangione is being cast as someone to admire. Luigi Nicholas Mangione is escorted into Blair County Courthouse on Tuesday in Hollidaysburg, Pa. Regina Bateson, an assistant political science professor at the University of Colorado at Boulder, has studied vigilantism, the term to which Shapiro alluded. She doesn’t see this case as a good fit for the word, she says, because the victim wasn’t linked to any specific crime or offense. As she sees it, it's more akin to domestic terrorism. But Bateson views the threats against election workers , prosecutors and judges ticking up — plus the assassination attempts against President-elect Donald Trump this past summer — as possible signs that personal grievances or political agendas could erupt. “Americans are voicing more support for — or at least understanding of — political violence,” she said. Shapiro praised the police and the people of Blair County, who abided by a 9/11-era dictum of seeing something and saying something. The commenters have Mangione wrong, the governor said: “Hear me on this: He is no hero. The real hero in this story is the person who called 911 at McDonald’s this morning." A person demonstrates Monday near the McDonald's restaurant in Altoona, Pennsylvania, where police earlier in the day arrested Luigi Nicholas Mangione, 26, in the Dec. 4 killing of UnitedHealthcare's CEO in Manhattan. Even shy of supporting violence, there are many instances of people who vent over how health insurers deny claims. Tim Anderson's wife, Mary, dealt with UnitedHealthcare coverage denials before she died from Lou Gehrig’s disease in 2022. “The business model for insurance is don’t pay,” Anderson, 67, of Centerville, Ohio, told The Associated Press . The discourse around the killing and Mangione is more than just memes. Conversations about the interconnectedness of various parts of American life are unfolding online as well. One Reddit user said he was banned for three days for supporting Kyle Rittenhouse, who was acquitted after testifying he acted in self-defense when he fatally shot two people in 2020 during protests. “Do you think people are getting banned for supporting Luigi?” the poster wondered. The comments cover a lot of ground. They include people saying the UnitedHealthcare slaying isn't a “right or left issue" and wondering what it would take to get knocked off the platform. “You probably just have to cross the line over into promoting violence,” one commenter wrote. “Not just laughing about how you don’t care about this guy.” Luigi Mangione is taken into the Blair County Courthouse on Tuesday in Hollidaysburg, Pa. Memes and online posts in support of the 26-year-old man, who's charged with killing UnitedHealthcare's CEO, have mushroomed online. Get the latest in local public safety news with this weekly email.CRM Lead Management Market is Booming Worldwide | Big Giants Salesforce, HubSpot, Microsoft DynamicsOklahoma residents on Sunday mourned the death of former Democratic U.S. Sen. Fred Harris, a trailblazer in progressive politics in the state who ran an unsuccessful presidential bid in 1976. Harris died on Saturday at 94. Democratic Party members across Oklahoma remembered Harris for his commitment to economic and social justice during the 1960s — a period of historical turbulence. Harris chaired the Democratic National Committee from 1969 to 1970 and helped unify the party after its tumultuous national convention in 1968 when protesters and police clashed in Chicago. “Fred Harris showed us what is possible when we lead with both heart and principle. He worked to ensure everyone had a voice and a seat at the table,” said Alicia Andrews, chair of the Oklahoma Democratic Party. Harris appeared at the Democratic National Convention in Chicago earlier this year as a guest speaker for the Oklahoma delegation, where he reflected on progress and unity. "Standing alongside him in Chicago this summer was a reminder of how his legacy continues to inspire,” Andrews said. Get the latest breaking news as it happens. By clicking Sign up, you agree to our privacy policy . Kalyn Free, a member of the Choctaw nation of Oklahoma and the DNC, said that there is no one else in public service whom she admired more than the former senator. “He was a friend, a mentor, a hero and my True North. Oklahoma and America have lost a powerful advocate and voice,” Free said in a statement. “His work for Indian Country will always be remembered.” Sen. Fred Harris of Oklahoma at a Democratic party commission meeting on March 1, 1969, in Washington. Credit: AP “Senator Harris truly was an Oklahoma treasure and was ahead of his time in so many ways,” said Jeff Berrong, whose grandfather served in the state Senate with Harris. “He never forgot where he came from and he always remained focused on building a society that would provide equality of opportunity for all.” Harris served eight years in the state Senate before he was elected to the U.S. Senate, where he served another eight years before his 1976 presidential campaign. State party leaders commemorated his work on the National Advisory Commission on Civil Disorders, or the Kerner Commission, to investigate the 1960s riots. Harris was the last surviving member of the commission. Shortly after his presidential campaign, Harris left politics and moved to New Mexico and became a political science professor at the University of New Mexico. —- Former Oklahoma Sen. Fred Harris stands outside his Corrales, N.M., home, Friday, July 23, 2004. Credit: AP/Jake Schoellkopf Lathan is a corps member for the Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues.

New funding goes to groundbreaking products that pour plant fibers into our favorite foods to reduce the toxic impact of sugar and lower the incidence of metabolic disorders linked to the modern processed diet SACRAMENTO, Calif. , Dec. 13, 2024 /PRNewswire/ -- One Bio , a pioneering biotechnology company committed to revolutionizing nutrition to empower people to live better, longer, has raised $27 million in Series A funding led by Alpha Edison and joined by new investors including Leaps by Bayer, Mitsui E12, Morado, ReMY, DSM-Ferminich, and Better – alongside existing investors including iSelect, Skyview Life Sciences, Collaborative and Acre. This catalytic investment round energized a unique global mix of strategic and institutional investors and is a testament to investor belief in One Bio's potential to reshape how much (and how often) the world consumes fiber, and to combat the disease epidemic linked to the modern processed diet by transforming your favorite foods into engines of good health while helping all of us reduce and eliminate the harm of sugar. One Bio has innovated a technological process that releases anti-inflammatory short chain fibers from thousands of plants, making them undetectable, more bioactive and uniquely high dose. This novel process unlocks fibers from seeds, nuts, fruits, vegetables, legumes and grains. People today consume 10X more sugar than they did 200 years ago and 90% less fiber than we evolved to. Consequently, 95% of people are running a dramatic fiber deficiency that starves the microbiome while denying our bodies of core functions for healthspan. The result is skyrocketing rates of inflammatory disease including obesity, diabetes, cardiovascular, neurodegenerative, cancer and autoimmunity. One Bio promises a meaningfully positive shift in these alarming public health outcomes by not only eliminating traditional barriers to fiber consumption - like taste, texture, and appearance - but also reframing naturally-derived fiber as an essential but *undetectable* ingredient in our favorite foods and beverages. As humans evolved, our beneficial gut microbes co-evolved to unlock and consume the sugars bound in the rich diversity of fibers present in plant foods to produce molecules we need to provide core functions including balancing our blood glucose, regulating mood & energy, and making us feel satiated. But modern diets composed of processed foods have isolated the sugars and discarded the fibers. One Bio short chain fibers can even provide an offramp to reduce the population's reliance on GLP-1s to treat chronic metabolic diseases: increasing consumption of high-fiber foods can prevent such diseases in the first place. "Modern food processing techniques strip plant fibers from our foods and starve the microbiome of the nutrients it needs to make us healthy. One Bio works to help us restore core functionality to our diet like blood glucose regulation and mood & energy balance. We aim to avoid and reverse the negative impact of today's processed food diet which accounts for 70% of calories consumed. We have the opportunity to offer industry and people an exponentially better set of choices than those on shelves today," said Matt Barnard , Co-founder and CEO of One Bio . " One Bio puts thriving microbiomes to work delivering longevity, aiding digestion and providing the fuel we need to maximize health," he added. "Faced with endless shelves of processed and packaged foods, and surrounded by chronic diseases, consumers are rapidly awakening to the power of the gut microbiome. An avalanche of signals points to a large pool of latent demand. This is One Bio's market," added Nate Redmond of Alpha Edison . " One Bio enables their partners to deliver functional products that reshape global health and unlock growth. We are thrilled to be working with Matt and the talented, passionate leaders who are building a category leading platform company. For more information about One Bio , please visit one.bio . About One Bio : One Bio is a biotechnology company returning healthspan to our diet by reintroducing active plant fibers to our food and reshaping how we approach health and nutrition in everyday products. Using their cutting-edge technology, One Bio has demonstrated its ability to solve malnutrition in the modern diet. The company specializes in releasing short chain fibers from plants, while making them easily consumable and highly effective to invigorate our microbiome and immune system. Through its innovative solutions and strategic partnerships, One Bio aims to eradicate inflammatory disease and help people thrive. Press contact: Original Strategies Simone Hassan-Bey simone@originalstrategies.com View original content to download multimedia: https://www.prnewswire.com/news-releases/one-bio-secures-27-million-in-series-a-funding-to-revolutionize-nutrition-with-launch-of-breakthrough-technology-making-high-dose-anti-inflammatory-plant-fiber-imperceptible-in-food-and-beverage-for-the-first-time-302331656.html SOURCE One BioDean McCullough's tears have been sneered at by some celebrities who insisted he "wasn't scared" when he was asked to role-play a mummified body and get buried up to the thigh in sand while having meal-worms thrown into his make-shift "sarcophagus". There's been even worse to come for the tearful I'm A Celebrity contestant, who couldn't stand being submerged in sand, as he seemed to receive a very icy rebuttal from Ant McPartlin on tonight's episode. The BBC Radio 1 star, who was nominated for a further trial, exactly as fans had predicted, attempted to crack a joke to relieve the tension. Turning to Ant and Dec, he exclaimed: "Well, well, well. We need to stop meeting like this. I've told you I didn't want another date!" While Declan Donnelly gamely laughed along, Ant gave a blank stare in his direction instead. Fans took to social media to address the apparent snub, with one writing: "Ant hates Dean so much omg his face says it all." A second agreed: "Ant can’t stand Dean. you can tell." A third viewer chimed in: "Ant literally looks like he hates Dean." Meanwhile, poor Dean's attentions might be more focused on the horrors of the trial ahead, after being nominated for the terrifying Jack and the Screamstalk trial. Tulisa made an unsuccessful attempt to reassure him, insisting that the trial wouldn't necessarily be "critter-related". Fortunately for her, she's exempt for "medical reasons" - and the public voted Dean to take on the responsibility. The BBC star has already attracted negative attention for being too theatrical during previous trials, as some refuse to believe that he's scared. He screamed, cried and almost hyperventilated his way through the infamous sarcophagus trial, prompting Strictly pro Ola Jordan and fellow dance champ husband James Jordan to debate on Twitter whether he was "acting". Ola claimed: "I don’t believe one bit that he was scared of that #ImACeleb." James then shot back: "I’m sure he’s a lovely guy but needs to work on his acting skills massively otherwise he will come across a bit fake as he’s definitely trying to play the game." Dean, who recently opened up about his battle with "hidden homelessness" , opted out of the trial after just two stars, yelling the code-word, "I'm A Celebrity, Get Me Out Of Here!" as he begged to be released. The decision made him less than popular with his hungry campmates, who'd been struggling alongside him in the jungle - and now fans are certain that Ant is acting frosty too.

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 ( Abstract #493 ) and MajesTEC-4 ( Abstract #494 ) studies establish the potential of TECVAYLI ® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting. 1,2 Forty-nine patients with transplant-eligible NDMM were treated with TECVAYLI ® in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj), lenalidomide and dexamethasone (Tec-DRd) or DARZALEX FASPRO ® , bortezomib, lenalidomide and dexamethasone (Tec-DVRd) as induction therapy in the MajesTEC-5 study. 1 All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10 -5 ) and maintained through cycle 6. 1 "These data from the MajesTEC-5 study build on the growing body of evidence of TECVAYLI combinations that support the potential combinability of TECVAYLI with other effective therapies, demonstrating high rates of MRD-negative responses for evaluable patients with newly diagnosed multiple myeloma," said Rachel Kobos, M.D., Vice President, Oncology Research & Development, Johnson & Johnson Innovative Medicine. "At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're committed to exploring the full potential of our therapies to improve outcomes for patients." The safety profiles were manageable and consistent with individual safety profiles. 1 No treatment-emergent adverse events (TEAEs) led to study treatment discontinuation or death; cytokine release syndrome (CRS; Grade 1 or 2) occurred in 65 percent of patients. 1 No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). 1 Grade 3/4 TEAEs included lymphopenia (43 percent), neutropenia (57 percent) and infections (35 percent). 1 "There remains opportunity to achieve even deeper and more sustained outcomes for a broader patient population in the frontline setting," said Marc S. Raab , M.D., Heidelberg University Hospital, Germany .* "These data reinforce the potential of TECVAYLI when used in earlier lines and show that TECVAYLI can be leveraged to optimize existing standard regimens in combination." Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of TECVAYLI ® to be administered as a maintenance therapy following autologous stem cell transplant (ASCT). 2 MajesTEC-4 is the first study to present data on a B-cell maturation antigen (BCMA) bispecific as monotherapy or combination therapy after ASCT. 2 Low rates of non-hematologic Grade 3/4 TEAEs and discontinuation of treatment due to all TEAEs (5.3 percent) were observed. CRS events were all Grade 1/2, mostly occurring during step-up dosing, and ICANS was not observed. Neutropenia and infections were the most common Grade 3/4 TEAEs. 2 Grade 3/4 neutropenia at 6 months showed a decreased trend in cohorts 2 and 3 with less frequent TECVAYLI ® dosing (cohort 1: 94 percent, cohort 2: 63 percent, cohort 3: 47 percent). 2 A similar trend was observed for all-grade infections (cohort 1: 94 percent; cohort 2: 78 percent; cohort 3: 77 percent). 2 All evaluable patients in cohort 1 who underwent MRD assessment after 12 months of therapy were MRD negative, and 100 percent of evaluable patients assessed in cohorts 2 and 3 were also MRD negative at cycle 6. 2 Further analysis of combination therapies will be evaluated in the Phase 3 MajesTEC-7 study, which is currently enrolling. About MajesTEC-5 Study MajesTEC-5 ( NCT05695508 ) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with newly diagnosed transplant eligible multiple myeloma. 3 About MajesTEC-4 Study MajesTEC-4 ( NCT05243797 ) is an ongoing, multicenter, randomized, open-label, Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation. 4 About MajesTEC-7 Study MajesTEC-7 ( NCT05552222 ) is a Phase 3 randomized study comparing teclistamab in combination with daratumumab SC and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab SC and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy. 5 About TECVAYLI ® TECVAYLI ® (teclistamab-cqyv) received approval from the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. 6 The European Commission (EC) granted TECVAYLI ® conditional marketing authorization (CMA) in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023 , the EC granted the approval of a Type II variation application for TECVAYLI ® , providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI ® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In February 2024 , the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months. For more information, visit www.TECVAYLI.com . About DARZALEX FASPRO ® and DARZALEX ® DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible. It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX FASPRO ® is co-formulated with recombinant human hyaluronidase PH20, Halozyme's ENHANZE ® drug delivery technology. DARZALEX ® is the first CD38-directed antibody approved to treat multiple myeloma. DARZALEX ® -based regimens have been used in the treatment of more than 585,000 patients worldwide and more than 239,000 patients in the U.S. alone. In August 2012 , Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. For more information, visit https://www.darzalexhcp.com. About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 7 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors. 8 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease. 9 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease. 10 People living with multiple myeloma have a 5-year survival rate of 59.8 percent. 11 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections. 12,13 TECVAYLI ® IMPORTANT SAFETY INFORMATION INDICATION AND USAGE TECVAYLI ® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). WARNINGS AND PRECAUTIONS Cytokine Release Syndrome - TECVAYLI ® can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI ® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients. Most patients experienced CRS following step-up dose 1 (42%), step-up dose 2 (35%), or the initial treatment dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI ® . The median time to onset of CRS was 2 (range: 1 to 6) days after the most recent dose with a median duration of 2 (range: 1 to 9) days. Clinical signs and symptoms of CRS included, but were not limited to, fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation). Initiate therapy according to TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Administer pretreatment medications to reduce risk of CRS and monitor patients following administration of TECVAYLI ® accordingly. At the first sign of CRS, immediately evaluate patient for hospitalization. Administer supportive care based on severity and consider further management per current practice guidelines. Withhold or permanently discontinue TECVAYLI ® based on severity. TECVAYLI ® is available only through a restricted program under a REMS. Neurologic Toxicity including ICANS - TECVAYLI ® can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI ® at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%). With longer follow-up, Grade 4 seizure and fatal Guillain-Barré syndrome (one patient each) occurred in patients who received TECVAYLI ® . In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI ® at the recommended dose. Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI ® . The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI ® based on severity per recommendations and consider further management per current practice guidelines. Due to the potential for neurologic toxicity, patients are at risk of depressed level of consciousness. Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI ® step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves. TECVAYLI ® is available only through a restricted program under a REMS. TECVAYLI ® and TALVEY ® REMS - TECVAYLI ® is available only through a restricted program under a REMS called the TECVAYLI ® and TALVEY ® REMS because of the risks of CRS and neurologic toxicity, including ICANS. Hepatotoxicity - TECVAYLI ® can cause hepatotoxicity, including fatalities. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, there was one fatal case of hepatic failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations in 0.6%. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Infections - TECVAYLI ® can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%. Monitor patients for signs and symptoms of infection prior to and during treatment with TECVAYLI ® and treat appropriately. Administer prophylactic antimicrobials according to guidelines. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Monitor immunoglobulin levels during treatment with TECVAYLI ® and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Neutropenia - TECVAYLI ® can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients. Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines. Monitor patients with neutropenia for signs of infection. Withhold TECVAYLI ® based on severity. Hypersensitivity and Other Administration Reactions - TECVAYLI ® can cause both systemic administration-related and local injection-site reactions. Systemic Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, 1.2% of patients experienced systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue. Local Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, injection-site reactions occurred in 35% of patients, with Grade 1 injection-site reactions in 30% and Grade 2 in 4.8%. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Embryo-Fetal Toxicity - Based on its mechanism of action, TECVAYLI ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TECVAYLI ® and for 5 months after the last dose. ADVERSE REACTIONS The most common adverse reactions (≥20%) were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets. Please read full Prescribing Information , including Boxed WARNING, for TECVAYLI ® . DARZALEX FASPRO ® INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: In combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant In combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor (PI) In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy As monotherapy in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DARZALEX FASPRO ® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation. WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO ® . Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO ® . Systemic Reactions In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO ® as monotherapy or in combination, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 0.7%, Grade 4: 0.1%). Systemic administration-related reactions occurred in 7% of patients with the first injection, 0.2% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 2.9 hours (range: 5 minutes to 3.5 days). Of the 165 systemic administration-related reactions that occurred in 93 patients, 144 (87%) occurred on the day of DARZALEX FASPRO ® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO ® . Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO ® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO ® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO ® . Local Reactions In this pooled safety population, injection-site reactions occurred in 7% of patients, including Grade 2 reactions in 0.8%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO ® . Monitor for local reactions and consider symptomatic management. Neutropenia Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO ® until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO ® , higher rates of Grade 3-4 neutropenia were observed. Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO ® until recovery of platelets. Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO ® can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO ® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO ® and for 3 months after the last dose. The combination of DARZALEX FASPRO ® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant women because lenalidomide, thalidomide, and pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide, or pomalidomide prescribing information on use during pregnancy. Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO ® . Type and screen patients prior to starting DARZALEX FASPRO ® . Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO ® -treated patients with IgG kappa myeloma protein. ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO ® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematology laboratory abnormalities (≥40%) with DARZALEX FASPRO ® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please click here to see the full Prescribing Information for DARZALEX FASPRO ® . About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com . Follow us at @JanssenUS and @JNJInnovMed . Janssen Research & Development, LLC and Janssen Biotech, Inc. are both Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TECVAYLI ® (teclistamab-cqyv ) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. * Marc S. Raab , M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. 1 Raab, Marc, S., et al, 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 2 Zamagni, Elena, et al., 494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 3 GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX). https://clinicaltrials.gov/study/NCT05695508 . Accessed November 2024 . 4 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4). https://clinicaltrials.gov/study/NCT05243797 . Accessed November 2024 . 5 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7). https://classic.clinicaltrials.gov/ct2/show/NCT05552222 . Accessed November 2024 . 6 U.S. FDA Approves TECVAYLI ® (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma . Accessed November 2024 . 7 Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-5672020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178 8 National Cancer Institute. Plasma Cell Neoplasms. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq . Accessed November 2024 . 9 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. https://www.cancercenter.com/cancer-types/multiple-myeloma . Accessed November 2024 . 10 American Cancer Society. Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html#:~:text=Multiple%20myeloma%20is%20a%20relatively,men%20and%2015%2C370%20in%20women . Accessed November 2024 . 11 SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/explorer/ . Accessed November 2024 . 12 American Cancer Society. What is Multiple Myeloma? https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html . Accessed November 2024 . 13 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html . Accessed November 2024 . SOURCE Johnson & JohnsonRico Carty, who won the 1970 NL batting title with the Atlanta Braves, has died

Biden calls for Assad to be 'held accountable'College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out

SANTA CLARA, Calif. , Dec. 13, 2024 /PRNewswire/ -- Marvell Technology, Inc. (NASDAQ: MRVL), today announced a quarterly dividend of $0.06 per share of common stock payable on January 30, 2025 to shareholders of record as of January 10, 2025 . About Marvell To deliver the data infrastructure technology that connects the world, we're building solutions on the most powerful foundation: our partnerships with our customers. Trusted by the world's leading technology companies for over 25 years, we move, store, process and secure the world's data with semiconductor solutions designed for our customers' current needs and future ambitions. Through a process of deep collaboration and transparency, we're ultimately changing the way tomorrow's enterprise, cloud, automotive, and carrier architectures transform—for the better. Marvell® and the Marvell logo are registered trademarks of Marvell and/or its affiliates. For further information, contact: Ashish Saran Senior Vice President, Investor Relations 408-222-0777 ir@marvell.com View original content to download multimedia: https://www.prnewswire.com/news-releases/marvell-technology-inc-declares-quarterly-dividend-payment-302331636.html SOURCE MarvellSANTA CLARA, Calif. , Dec. 13, 2024 /PRNewswire/ -- Marvell Technology, Inc. (NASDAQ: MRVL), today announced a quarterly dividend of $0.06 per share of common stock payable on January 30, 2025 to shareholders of record as of January 10, 2025 . About Marvell To deliver the data infrastructure technology that connects the world, we're building solutions on the most powerful foundation: our partnerships with our customers. Trusted by the world's leading technology companies for over 25 years, we move, store, process and secure the world's data with semiconductor solutions designed for our customers' current needs and future ambitions. Through a process of deep collaboration and transparency, we're ultimately changing the way tomorrow's enterprise, cloud, automotive, and carrier architectures transform—for the better. Marvell® and the Marvell logo are registered trademarks of Marvell and/or its affiliates. For further information, contact: Ashish Saran Senior Vice President, Investor Relations 408-222-0777 ir@marvell.com View original content to download multimedia: https://www.prnewswire.com/news-releases/marvell-technology-inc-declares-quarterly-dividend-payment-302331636.html SOURCE MarvellBrazilian tennis player Joao Lucas Reis Da Silva has made history with a single Instagram post . Reis Da Silva recently took to Instagram to share a sweet tribute celebrating his partner, Gui Sampaio Ricardo's birthday. While on first glance it may seem like any regular birthday tribute, the post makes Reis Da Silva the first gay male tennis player to be open about his sexuality while still active on the tennis circuit. READ MORE: Jim Carrey retired from acting. One thing forced him to come back In the year 2024, it may seem strange that we're only now seeing this piece of history marked, but former tennis players such as Brian Vahaly – who opened up about his sexuality following his retirement – have explained why it may be so. "Tennis is perceived as that country club sport, a highly competitive individual sport played across every country of the world. There are a lot of reasons not to come out as a gay man," he told The Telegraph in 2018 after sharing his sexual orientation on a 2017 podcast episode. "Outside of the States and Europe, there are a lot of countries not accepting of gay men. It's not a team sport; there are not teammates on whom you can rely – you practice with your competitors." He added that because of "a lot of homophobic locker room comments made in jest", the professional tennis circuit never felt like a safe space for him to be open about his sexuality.  As Vahaly pointed out, tennis is a sport that sees its players travel the world to compete in tournaments from an amateur level all the way up to the pros. With homosexuality still criminalised in 64 countries with penalties including life in prison and even the death penalty in 12 of those countries, it's no wonder players in the spotlight have often kept their sexuality to themselves. READ MORE: How a bag of frozen peas could save your dog's li It's a battle that's been publicly fought by tennis stars for close to a century now, likely even longer. In 1917, Danish tennis player Leif Rovsing – who competed in both the singles and doubles competitions at the 1912 Summer Olympics – was banned from the sport for "presumed homosexuality." "Mr. Rovsing's morality is of such a nature that it stands in open conflict with the task of all healthy sports, to promote bodily and spiritual health," the Danish tennis authorities said of his ban at the time. Rovsing was said to have never attempted to keep his sexuality a secret, and spent the rest of his life unapologetically defending the LGBTQIA+ community's right to play professional sport. Despite dedicating his life to campaign for the acceptance of homosexuality in sport, Rovsing's ban was never revoked. For a daily dose of 9honey, subscribe to our newsletter here . Unable to ever return to professional tennis, Rovsing was instead forced to commission, design and decorate the Dansk Tennis Club in Copenhagen where he could continue to enjoy his sport in what is now considered one of the most decadent places to play tennis in the world. After being outed in 1981, Billie Jean King paved the way for gay female tennis players when she ignored her lawyers' advice to deny claims she was a lesbian. "I said, 'I'm going to do it. I don't care. This is important to me to tell the truth'," King told NBC News in 2017. "The one thing my mother always said, 'To thine own self be true'." Over the years several female tennis players have been open about their sexuality, but that doesn't mean they've had an easy go of it either.  READ MORE: The key ingredient in this delicious dish might shock you.  Top Russian tennis player Daria Kasatinka shared her sexuality in a 2022 YouTube interview, saying, "Living in peace with yourself is the only thing that matters, and f--k everyone else." In the following years, she has shared that her sexuality is one of the reasons she can no longer live in her home country, adding that she has no plans to return and openly criticising Russia's conservative political environment. "It's unsafe for me now, with the regime we have," she said in 2023. "As a gay person who opposes the war, it's not possible to go back... But I don't regret it even 1 per cent." FOLLOW US ON WHATSAPP HERE : Stay across all the latest in celebrity, lifestyle and opinion via our WhatsApp channel. No comments, no algorithm and nobody can see your private details.